Drug firm Mankind Pharma today said it has received licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of COVID-19.
2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior. The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy's Laboratories, Mankind Pharma said in a statement.
The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added.
The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe COVID-19 patients, Mankind Pharma said.
The drug is found to help the hospitalised COVID-19 patients recover faster and is also known to reduce the supplemental oxygen dependency among the COVID-19 patients, it added.
"Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic," the company said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
DRDO Invites Applications For Various Positions, Salary Up To Rs 1.25 Lakh Per Month DRDO Invites Applications For Research Associate And Junior Research Fellow DRDO, IIT-Delhi Develop Lightweight Bulletproof Jackets With 360-Degree Protection Aligarh Muslim University A Minority Institution? Supreme Court's Key 4:3 Verdict Elon Musk Replies To 'We Need Your Help Removing Trudeau' Post "Did Entire World A Favour": Minister On Why India Buys Russian Oil India Deserves To Be In List Of Global Superpowers: Vladimir Putin DY Chandrachud's Last Working Day: What Do Chief Justices Do After Term Ends 2024 Maruti Suzuki Dzire Bags 5-Star GNCAP Rating, Delivers 25.71 Kmpl Track Latest News Live on NDTV.com and get news updates from India and around the world.